NO20034232L - Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser - Google Patents

Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser

Info

Publication number
NO20034232L
NO20034232L NO20034232A NO20034232A NO20034232L NO 20034232 L NO20034232 L NO 20034232L NO 20034232 A NO20034232 A NO 20034232A NO 20034232 A NO20034232 A NO 20034232A NO 20034232 L NO20034232 L NO 20034232L
Authority
NO
Norway
Prior art keywords
glucocorticoid receptor
treatment
stress disorders
specific antagonists
methods
Prior art date
Application number
NO20034232A
Other languages
English (en)
Other versions
NO20034232D0 (no
NO334745B1 (no
Inventor
Joseph K Belanoff
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of NO20034232D0 publication Critical patent/NO20034232D0/no
Publication of NO20034232L publication Critical patent/NO20034232L/no
Publication of NO334745B1 publication Critical patent/NO334745B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Oppfinnelsen angår generelt området psykiatri. Spesielt angår foreliggende oppfinnelse oppdagelsen at midler som inhiberer bindingen av kortisol til sine reseptorer kan bli brukt ved fremgangsmåter for å behandle stresslidelser. Oppfinnelsen gjelder anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament for å lindre symptomene av en stresslidelse, samt glukokortikoidreseptorantagonist for anvendelse i fremgangsmåte for å lindre symptomene av en stresslidelse. Mifepriston som er en spesifikk glukokortikoidreseptorantagonist kan bli brukt i disse metoder.
NO20034232A 2001-03-23 2003-09-23 Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser NO334745B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27852301P 2001-03-23 2001-03-23
PCT/US2002/008622 WO2002076390A2 (en) 2001-03-23 2002-03-19 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists

Publications (3)

Publication Number Publication Date
NO20034232D0 NO20034232D0 (no) 2003-09-23
NO20034232L true NO20034232L (no) 2003-11-21
NO334745B1 NO334745B1 (no) 2014-05-19

Family

ID=23065304

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034232A NO334745B1 (no) 2001-03-23 2003-09-23 Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser

Country Status (16)

Country Link
US (1) US6964953B2 (no)
EP (1) EP1370268B1 (no)
JP (2) JP2004525135A (no)
KR (1) KR100895662B1 (no)
CN (2) CN1556709A (no)
AU (1) AU2002255845B2 (no)
CA (1) CA2440605C (no)
DE (1) DE60232956D1 (no)
DK (1) DK1370268T3 (no)
ES (1) ES2326364T3 (no)
IL (2) IL157770A0 (no)
NO (1) NO334745B1 (no)
NZ (1) NZ528147A (no)
PT (1) PT1370268E (no)
WO (1) WO2002076390A2 (no)
ZA (1) ZA200307066B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
EP1441739B1 (en) * 2001-10-26 2006-02-15 Akzo Nobel N.V. Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
US8193172B2 (en) 2001-11-23 2012-06-05 Pop Test Cortisol Llc Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
EP2270034A3 (en) 2004-06-03 2011-06-01 Athlomics Pty Ltd Agents and methods for diagnosing stress
WO2008137270A1 (en) * 2007-05-04 2008-11-13 H. Lundbeck A/S Methods of diagnosing and monitoring of npy y5 based disorders
US8598149B2 (en) 2007-08-30 2013-12-03 Corcept Therapeutics, Inc. Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
US11103514B2 (en) * 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JP5804395B2 (ja) * 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
EP3231421A1 (en) * 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
US11045482B2 (en) 2017-03-09 2021-06-29 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
AU2019414333A1 (en) * 2018-12-28 2021-08-05 Panda Consulting Llc Short-acting selective glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1261165B (it) * 1993-01-25 1996-05-09 Polifarma Spa Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
WO1999017779A1 (en) 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
NZ334627A (en) * 1999-03-12 2002-07-26 Horticulture & Food Res Inst A therapeutic composition containing a therapeutic agent such as an anthelmintic and an antistress agent such as metyrapone or a nitric oxide promoter for increasing efficacy of therapeutic agents and animal growth
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
IL157770A0 (en) 2004-03-28
JP2004525135A (ja) 2004-08-19
KR20030093266A (ko) 2003-12-06
DK1370268T3 (da) 2009-09-14
ES2326364T3 (es) 2009-10-08
NO20034232D0 (no) 2003-09-23
US20020169152A1 (en) 2002-11-14
US6964953B2 (en) 2005-11-15
NZ528147A (en) 2005-06-24
AU2002255845B2 (en) 2006-11-23
IL157770A (en) 2010-11-30
WO2002076390A3 (en) 2003-05-22
KR100895662B1 (ko) 2009-05-07
CN1820756A (zh) 2006-08-23
EP1370268A2 (en) 2003-12-17
CN1556709A (zh) 2004-12-22
JP2009102412A (ja) 2009-05-14
CA2440605C (en) 2012-01-10
PT1370268E (pt) 2009-08-26
DE60232956D1 (de) 2009-08-27
EP1370268B1 (en) 2009-07-15
NO334745B1 (no) 2014-05-19
EP1370268A4 (en) 2005-02-09
CA2440605A1 (en) 2002-10-03
WO2002076390A2 (en) 2002-10-03
ZA200307066B (en) 2004-09-10

Similar Documents

Publication Publication Date Title
NO20034232L (no) Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser
CY1119768T1 (el) Συνθεση περιλαμβανουσα νικοτινη και οπιπραμολη και χρηση αυτης
NO20056134L (no) Kombinasjon av en NMDA-reseptorantagonist og en selektiv serotoningjenopptaksinbibitor for behandling av depresjon og andre sinnsstemningsforstyrrelser
ATE332696T1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
NO20061412L (no) Terapi av okulaere foretyrrelser
NO20065252L (no) Behandling av forstyrrelser
SG165316A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
WO2006105117A3 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
NO20072188L (no) Bundne forbindelser som CGRP-reseptorantagonister
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EA200400337A1 (ru) Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
MA34646B1 (fr) Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17
NO20092718L (no) Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer
NO20091949L (no) Sammensetninger og fremgangsmater for modulering av C-kit og PDGFR-reseptorer
BRPI0511660A (pt) combinação, produto, kit de partes, embalagem, uso de um antagonista de receptores muscarìnicos m3 e de um agonista beta2, e, método para tratar um paciente sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
WO2004082602A3 (en) Carboxamide spirohydantoin cgrp receptor antagonists
WO2005112903A3 (en) Use of ghrelin antagonists for improving cognition and memory
ATE450508T1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
WO2007067617A3 (en) Use of a cb1 antagonist for treating negative symptoms of schizophrenia
MXPA05007381A (es) Metodo para el tratamiento de transtornos funcionales del intestino.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees